Folate receptor-targeted immunotherapy of cancer: Mechanism and therapeutic potential

Advanced Drug Delivery Reviews

Volumn 56, Issue 8, 2004, Pages 1161-1176

  Lu, Yingjuan ^a   Sega, Emanuela ^b   Leamon, Christopher P ^a   Low, Philip S ^b  

^a Endocyte Inc   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Cancer immunotherapy; Cytokine stimulation; Fc expressing immune cells; Folate receptor; Targeting of folate hapten conjugates

Indexed keywords

AGENTS; ANTIBODIES; ANTIGENS; CELLS; DRUG DOSAGE; DRUG THERAPY; TUMORS;

FOLATE-RECEPTOR (FR); FOLATE-TARGETED CANCER THERAPIES; THERAPEUTIC AGENTS; TUMOR-ASSOCIATED ANTIGEN;

IMMUNOLOGY;

ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; FC RECEPTOR; FLUORESCEIN ISOTHIOCYANATE; FOLATE RECEPTOR; FOLIC ACID; HAPTEN; HAPTEN ANTIBODY; IBRITUMOMAB TIUXETAN; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MEMBRANE RECEPTOR; MYELOTARG; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HOST; HUMAN; IMMUNOCOMPETENCE; IMMUNOGENICITY; IMMUNOSURVEILLANCE; KIDNEY DISEASE; LIVER DISEASE; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TARGET CELL; TUMOR CELL;

EID: 1942503277     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2004.01.009     Document Type: Article

References (114)

1. Costello R.T., Gastaut J.A., Olive D. Tumor escape from immune surveillance. Arch. Immunol. Ther. Exp. 47:1999;83-88.
2. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3:2002;999-1005.
3. Klein L., Trautman L., Psarras S., Schnell S., Siermann A., Liblau R., et al. Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor. Eur. J. Immunol. 33:2003;806-814.
4. Bodey B., Bodey B. Jr., Siegel S.E., Kaiser H.E. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. 20:2000;2665-2676.
5. Mitchell M.S. Cancer vaccines, a critical review - Part I. Curr. Opin. Invest. Drugs. 3:2002;140-149.
6. Mitchell M.S. Cancer vaccines, a critical review - Part II. Curr. Opin. Invest. Drugs. 3:2002;150-158.
7. Reilly R.T., Emens L.A., Jaffee E.M. Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer? Curr. Opin. Invest. Drugs. 2:2001;133-135.
8. Lu Y., Low P.S. Targeted immunotherapy of cancer: development of antibody-induced cellular immunity. J. Pharm. Pharmacol. 55:2003;163-167.
9. Campbell I.G., Jones T.A., Foulkes W.D., Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res. 51:1991;5329-5338.
10. Weitman S.D., Lark R.H., Coney L.R., Fort D.W., Frasca V., Zurawski V.R. Jr., Kamen B.A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52:1992;3396-3401.
11. Weitman S.D., Frazier K.M., Kamen B.A. The folate receptor in central nervous system malignancies of childhood. J. Neuro-Oncol. 21:1994;107-112.
12. Toffoli G., Cernigoi C., Russo A., Gallo A., Bagnoli M., Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer. 74:1997;193-198.
13. Holm J., Hansen S.I., Hoier-Madsen M., Christensen T.B., Nichols C.W. Characterization of a high-affinity folate receptor in normal and malignant human testicular tissue. Biosci. Rep. 19:1999;571-580.
14. Ross J.F., Wang H., Behm F.G., Mathew P., Wu M., Booth R., Ratnam M. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer. 85:1999;348-357.
15. Bueno R., Appasani K., Mercer H., Lester S., Sugarbaker D. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 121:2001;225-233.
16. Vastag B. Folate gains momentum as a vehicle for drug delivery. J. Natl. Cancer Inst. 92:2000;1800-1801.
17. Leamon C.P., Parker M.A., Vlahov I.R., Xu L.C., Reddy J.A., Vetzel M., Douglas N. Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical. Bioconjug. Chem. 13:2002;1200-1210.
18. 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J. Nucl. Med. 44:2003;700-707.
19. Leamon C.P., Low P.S. Selective targeting of malignant cells with cytotoxin-folate conjugates. J. Drug Target. 2:1994;101-112.
20. Atkinson S.F., Bettinger T., Seymour L.W., Behr J.P., Ward C.M. Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells. J. Biol. Chem. 276:2001;27930-27935.
21. Ladino C.A., Chari R.V., Bourret L.A., Kedersha N.L., Goldmacher V.S. Folate-maytansinoids: target-selective drugs of low molecular weight. Int. J. Cancer. 73:1997;859-864.
22. Goren D., Horowitz A.T., Tzemach D., Tarshish M., Zalipsky S., Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 6:2000;1949-1957.
23. Gosselin M.A., Lee R.J. Folate receptor-targeted liposomes as vectors for therapeutic agents. Biotechnol. Annu. Rev. 8:2002;103-131.
24. Konda S.D., Aref M., Wang S., Brechbiel M., Wiener E.C. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. Magma. 12:2001;104-113.
25. Moon W.K., Lin Y., O'Loughlin T., Tang Y., Kim D.E., Weissleder R., Tung C.H. Enhanced tumor detection using a folate receptor-targeted near-infrared fluorochrome conjugate. Bioconjug. Chem. 14:2003;539-545.
26. Kennedy M.D., Jallad K.N., Lu J., Low P.S., Ben-Amotz D. Evaluation of folate conjugate uptake and transport by the choroid plexus of mice. Pharm. Res. 20:2003;714-719.
27. Shukla S., Wu G., Chatterjee M., Yang W., Sekido M., Diop L.A., et al. Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. Bioconjug. Chem. 14:2003;158-167.
28. Lee R.J., Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 269:1994;3198-3204.
29. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Mandelbaum-Shavit F., Qazen M.M., Zalipsky S. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug. Chem. 10:1999;289-298.
30. Ward C.M. Folate-targeted non-viral DNA vectors for cancer gene therapy. Curr. Opin. Mol. Ther. 2:2000;182-187.
31. Xu L., Pirollo K.F., Chang E.H. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J. Control. Release. 74:2001;115-128.
32. Reddy J.A., Abburi C., Hofland H., Howard S.J., Vlahov I., Wils P., Leamon C.P. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther. 9:2002;1542-1550.
33. Patrick T.A., Kranz D.M., Zachary J.F., Roy E.J. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors. Int. J. Cancer. 78:1998;470-479.
34. Rund L.A., Cho B.K., Manning T.C., Holler P.D., Roy E.J., Kranz D.M. Bispecific agents target endogenous murine T cells against human tumor xenografts. Int. J. Cancer. 83:1999;141-149.
35. Cho B.K., Roy E.J., Patrick T.A., Kranz D.M. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells. Bioconjug. Chem. 8:1997;338-346.
36. Kranz D.M., Manning T.C., Rund L.A., Cho B.K., Gruber M.M., Roy E.J. Targeting tumor cells with bispecific antibodies and T cells. J. Control. Release. 53:1998;77-84.
37. Roy E.J., Cho B.K., Rund L.A., Patrick T.A., Kranz D.M. Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate. Int. J. Cancer. 76:1998;761-766.
38. Lu Y., Low P.S. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother. 51:2002;153-162.
39. Lu Y., Low P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 54:2002;675-693.
40. Lu Y., Low P.S. Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospect. J. Control. Release. 91:2003;17-29.
41. Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases, 1893. Clin. Orthop. 1991;3-11.
42. Wiemann B., Starnes C.O. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 64:1994;529-564.
43. White C.A., Weaver R.L., Grillo-Lopez A.J. Antibody-targeted immunotherapy for treatment of malignancy. Annu. Rev. Med. 52:2001;125-145.
44. Foss F.M. Immunologic mechanisms of antitumor activity. Semin. Oncol. 29:2002;5-11.
45. Slingluff C.L. Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms [see comments]. Cancer Immunol. Immunother. 48:1999;371-373.
46. Wang R.F., Rosenberg S.A. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170:1999;85-100.
47. Coulie P.G., Hanagiri T., Takenoyama M. From tumor antigens to immunotherapy. Int. J. Clin. Oncol. 6:2001;163-170.
48. Jager D., Jager E., Knuth A. Immune responses to tumour antigens: implications for antigen-specific immunotherapy of cancer. J. Clin. Pathol. 54:2001;669-674.
49. Jager D., Jager E., Bert F., Knuth A. Cellular and humoral immune responses of cancer patients to defined tumor antigens. Cancer Chemother. Biol. Response Modif. 19:2001;385-393.
50. Restifo N.P., Esquivel F., Kawakami Y., Yewdell J.W., Mule J.J., Rosenberg S.A., Bennink J.R. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177:1993;265-272.
51. Igney F.H., Krammer P.H. Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukocyte Biol. 71:2002;907-920.
52. Carbone J.E., Ohm D.P. Immune dysfunction in cancer patients. Oncology (Huntingt). 16:2002;11-18.
53. Hadden J.W. Immunodeficiency and cancer: prospects for correction. Int. Immunopharmacol. 3:2003;1061-1071.
54. Weiner L.M. Monoclonal antibody therapy of cancer. Semin. Oncol. 26:1999;43-51.
55. Cohen P.A., Peng L., Kjaergaard J., Plautz G.E., Finke J.H., Koski G.K., et al. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Crit. Rev. Immunol. 21:2001;215-248.
56. Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Opin. Biol. Ther. 2:2002;335-342.
57. Ward S., Casey D., Labarthe M.C., Whelan M., Dalgleish A., Pandha H., Todryk S. Immunotherapeutic potential of whole tumour cells. Cancer Immunol. Immunother. 51:2002;351-357.
58. Lopez J.A., Hart D.N. Current issues in dendritic cell cancer immunotherapy. Curr. Opin. Mol. Ther. 4:2002;54-63.
59. Donnelly J.J., Ulmer J.B., Liu M.A. DNA vaccines. Dev. Biol. Stand. 95:1998;43-53.
60. Manjili M.H., Wang X.Y., Park J., Facciponte J.G., Repasky E.A., Subjeck J.R. Immunotherapy of cancer using heat shock proteins. Front. Biosci. 7:2002;d43-d52.
61. van Spriel A.B., van Ojik H.H., van De Winkel J.G. Immunotherapeutic perspective for bispecific antibodies. Immunol. Today. 21:2000;391-397.
62. Bhattacharya-Chatterjee M., Chatterjee S.K., Foon K.A. Anti-idiotype vaccine against cancer. Immunol. Lett. 74:2000;51-58.
63. Dachs G.U., Dougherty G.J., Stratford I.J., Chaplin D.J. Targeting gene therapy to cancer: a review. Oncol. Res. 9:1997;313-325.
64. Pawelec G., Rees R.C., Kiessling R., Madrigal A., Dodi A., Baxevanis C., et al. Cells and cytokines in immunotherapy and gene therapy of cancer. Crit. Rev. Oncog. 10:1999;83-127.
65. Yoshizawa H., Kagamu H., Gejyo F. Cancer immunogene therapy. Arch. Immunol. Ther. Exp. 49:2001;337-343.
66. Green M.C., Murray J.L., Hortobagyi G.N. Monoclonal antibody therapy for solid tumors. Cancer Treat. Rev. 26:2000;269-286.
67. Mocellin S., Rossi C.R., Lise M., Marincola F.M. Adjuvant immunotherapy for solid tumors: from promise to clinical application. Cancer Immunol. Immunother. 51:2002;583-595.
68. Rijnboutt S., Jansen G., Posthuma G., Hynes J.B., Schornagel J.H., Strous G.J. Endocytosis of GPI-linked membrane folate receptor-alpha. J. Cell Biol. 132:1996;35-47.
69. Matherly L.H., Goldman D.I. Membrane transport of folates. Vitam. Horm. 66:2003;403-456.
70. Sudimack J., Lee R.J. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 41:2000;147-162.
71. Toffoli G., Russo A., Gallo A., Cernigoi C., Miotti S., Sorio R., et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int. J. Cancer. 79:1998;121-126.
72. Wu M., Gunning W., Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol. Biomarkers Prev. 8:1999;775-782.
73. Peoples G.E., Anderson B.W., Lee T.V., Murray J.L., Kudelka A.P., Wharton J.T., Ioannides C.G. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers. Clin. Cancer Res. 5:1999;4214-4223.
74. Whiteside T.L. 22. Immune responses to malignancies. J. Allergy Clin. Immunol. 111:2003;S677-686.
75. Kennedy M.D., Jallad K.N., Thompson D.H., Ben-Amotz D., Low P.S. Optical imaging of metastatic tumors using a folate-targeted fluorescent probe. J. Biomed. Opt. 8:2003;636-641.
76. Musselli C., Livingston P.O., Ragupathi G. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience. J. Cancer Res. Clin. Oncol. 127:(Suppl. 2):2001;R20-R26.
77. Anderson C.F., Mosser D.M. Cutting edge: biasing immune responses by directing antigen to macrophage Fc gamma receptors. J. Immunol. 168:2002;3697-3701.
78. Dredge K., Marriott J.B., Todryk S.M., Dalgleish A.G. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol. Immunother. 51:2002;521-531.
79. Steplewski Z., Lubeck M.D., Scholz D., Loibner H., McDonald Smith J., Koprowski H. Tumor cell lysis and tumor growth inhibition by the isotype variants of MAb BR55-2 directed against Y oligosaccharide. In Vivo. 5:1991;79-83.
80. Koh C.Y., Yuan D. The functional relevance of NK-cell-mediated upregulation of antigen-specific IgG2a responses. Cell. Immunol. 204:2000;135-142.
81. Baldridge J.R., Crane R.T. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods. 19:1999;103-107.
82. Persing D.H., Coler R.N., Lacy M.J., Johnson D.A., Baldridge J.R., Hershberg R.M., Reed S.G. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 10:2002;S32-S37.
83. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA. 94:1997;10833-10837.
84. Miconnet I., Koenig S., Speiser D., Krieg A., Guillaume P., Cerottini J.C., Romero P. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J. Immunol. 168:2002;1212-1218.
85. Kensil C.R. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carrier Syst. 13:1996;1-55.
86. Marciani D.J., Press J.B., Reynolds R.C., Pathak A.K., Pathak V., Gundy L.E., et al. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine. 18:2000;3141-3151.
87. Allison A.C. Immunological adjuvants and their modes of action. Arch. Immunol. Ther. Exp. (Warsz). 45:1997;141-147.
88. Rodolfo M., Melani C., Zilocchi C., Cappetti B., Luison E., Arioli I., et al. IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases. Cancer Res. 58:1998;5812-5817.
89. Lussow A.R., Fanget L., Gao L., Block M., Buelow R., Pouletty P. Targeting of antihapten antibodies to activated T cells via an IL-2-hapten conjugate prolongs cardiac graft survival. Transplantation. 62:1996;1703-1708.
90. Lussow A.R., Buelow R., Fanget L., Peretto S., Gao L., Pouletty P. Redirecting circulating antibodies via ligand-hapten conjugates eliminates target cells in vivo. J. Immunother. Emphasis Tumor Immunol. 19:1996;257-265.
91. van de Winkel J.G., Capel P.J. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today. 14:1993;215-221.
92. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 99:2002;754-758.
93. Ernst L.K., Metes D., Herberman R.B., Morel P.A. Allelic polymorphisms in the FcgammaRIIC gene can influence its function on normal human natural killer cells. J. Mol. Med. 80:2002;248-257.
94. Vuist W.M., Visseren M.J., Otsen M., Bos K., Vyth-Dreese F.A., Figdor C.G., et al. Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alpha. Cancer Immunol. Immunother. 36:1993;163-170.
95. Caron P.C., Lai L.T., Scheinberg D.A. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. Clin. Cancer Res. 1:1995;63-70.
96. Flieger D., Spengler U., Beier I., Sauerbruch T., Schmidt-Wolf I. Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2. Cytokine. 12:2000;756-761.
97. Ozaki S., Kosaka M., Wakahara Y., Ozaki Y., Tsuchiya M., Koishihara Y., et al. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood. 93:1999;3922-3930.
98. Sondel P.M., Hank J.A. Antibody-directed, effector cell-mediated tumor destruction. Hematol. Oncol. Clin. North Am. 15:2001;703-721.
99. Liu Z., Lee F.T., Hanai N., Smyth F.E., Burgess A.W., Old L.J., Scott A.M. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871. Cancer Immun. 2:2002;13.
100. Liu Z., Smyth F.E., Renner C., Lee F.T., Oosterwijk E., Scott A.M. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol. Immunother. 51:2002;171-177.
101. Muller L., Pawelec G. Cytokines and antitumor immunity. Technol. Cancer Res. Treat. 2:2003;183-194.
102. Brassard D.L., Grace M.J., Bordens R.W. Interferon-alpha as an immunotherapeutic protein. J. Leukocyte Biol. 71:2002;565-581.
103. Belardelli F., Ferrantini M., Proietti E., Kirkwood J.M. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13:2002;119-134.
104. Farah C.S., Elahi S., Pang G., Gotjamanos T., Seymour G.J., Clancy R.L., Ashman R.B. T cells augment monocyte and neutrophil function in host resistance against oropharyngeal candidiasis. Infect. Immun. 69:2001;6110-6118.
105. Korbelik M., Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett. 137:1999;91-98.
106. Dyall R., Vasovic L.V., Clynes R.A., Nikolic-Zugic J. Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor. Eur. J. Immunol. 29:1999;30-37.
107. Bukowski R.M. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 80:1997;1198-1220.
108. Bukowski R.M. Cytokine therapy for metastatic renal cell carcinoma. Semin. Urol. Oncol. 19:2001;148-154.
109. Tirapu I., Mazzolini G., Rodriguez-Calvillo M., Arina A., Palencia B., Gabari I., Melero I. Effective tumor immunotherapy: start the engine, release the brakes, step on the gas pedal,...and get ready to face autoimmunity. Arch. Immunol. Ther. Exp. 50:2002;13-18.
110. Turk M.J., Wolchok J.D., Guevara-Patino J.A., Goldberg S.M., Houghton A.N. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol. Rev. 188:2002;122-135.
111. Bernhard H., Salazar L., Schiffman K., Smorlesi A., Schmidt B., Knutson K.L., Disis M.L. Vaccination against the HER-2/neu oncogenic protein. Endocr. Relat. Cancer. 9:2002;33-44.
112. Cohen Y., Polliack A., Zelig O., Goldfarb A. Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma. Leuk. Lymphoma. 42:2001;1405-1408.
113. Livingston P.O., Ragupathi G., Musselli C. Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues. J. Clin. Immunol. 20:2000;85-93.
114. Franzke A., Peest D., Probst-Kepper M., Buer J., Kirchner G.I., Brabant G., et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J. Clin. Oncol. 17:1999;529-533.